# A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

> **NCT01597648** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 42 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus I

## Interventions

- **DRUG:** Maraviroc
- **DRUG:** Combivir
- **DRUG:** GSK2838510

## Key facts

- **NCT ID:** NCT01597648
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597648, "A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01597648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*